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Effects of HMG-CoA reductase inhibitors in hypercholesterolemic
patients on hemodialysis. The efficacy of lovastatin and simvastatin,
competitive inhibitors of 3hydroxy-3-methy1 glutaryl coenzyme A
reductase, was investigated in 40 hemodialysis (HD) patients displaying
hypercholesterolemia and moderate hypertriglyceridemia (selection of
40 patients required screening of 700 hemodialysis patients). After a
four-week placebo period, lovastatin or simvastatin was administered
to two groups of 20 patients in increasing doses over a period of three
months. Thirty-six patients completed the study. Lovastatin (1st month
20mg; 2nd and 3rd months 40mg day ') and simvastatin (1st month 10
mg, 2nd month 20 mg and 3rd month 40 mg day ')reduced total serum
cholesterol from 280.3 9.4 to 213.0 6.7 (—24%) and 295.0 12.2 to
202.3 8.9 mg/dl (—31.4%), LDL cholesterol from 161.9 10.7 to
112.1 7.9 (—30.8%) and 181.8 14.7 to 107.4 8.1 mg/dl (—40.9%),
as well as apolipoprotein B (apo B) from 116.0 6.6 to 83,3 3.7
(—28.2%) and 134.4 8.2 to 84.1 5.3 mg/dl (—37.4%), respectively.
Furthermore, the ratio of LDL apo B/LDL cholesterol increased
significantly (0.63 0.02 vs. 0.71 0.05 and 0.63 0.02 vs. 0.66
0.02, respectively). Another remarkable effect was the reduction of
cholesterol concentration in VLDL (72.4 8.9 vs. 47.3 6.8 [lovas-
tatini and 78.3 11.1 vs. 50.7 8.8 mg/dl [simvastatin], respectively).
Therefore, the ratio of triglycerides/cholesterol in VLDL increased (3.2
0.2 vs. 3.8 0.3 and 3.2 0.2vs. 4.0 0.2, respectively), indicating
VLDL formation poor in cholesterol and rich in triglycerides. The main
difference between the two drugs was that only simvastatin significantly
reduced triglycerides but increased HDL cholesterol and apolipopro-
tein A-I. Although one patient developed a moderate increase in
hepatic transaminases, the other 35 patients had no notable side effects.
Measurement of simvastatin plasma levels 13.4 hours after drug admin-
istration showed plasma values between 4 and 45 ng/ml (in controls not
detectable after 12 hr). At present, it appears that there are only a few
selected patients with high serum cholesterol level among all HD
patients who could be candidates for the treatment with HMG-CoA
reductase inhibitors.
In patients with chronic renal failure there is current debate
as to whether cardiovascular disease is accelerated or not [1—8].
The pattern of dyslipidemia in dialysis patients include those
with mild hypertriglyceridemia and a decreased concentration
of high density lipoprotein [9]. This group represents the major
form of dyslipidemia. Although the reduction of plasma lipo-
proteins may diminish the risk of atherosclerosis [10, 11], the
contribution of hypertriglyceridemia to coronary heart disease
is conjectural. Therefore, it is also unclear whether this form of
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dyslipidemia should specifically be treated [reviewed in 12] and
certainly no rationale exists to induce LDL receptors in these
patients. On the other hand, Nestel, Fidge and Tan [13] and
Minamisono and coworkers [141 described a group of TT1D
patients with a predominant increase in lipoprotein remnants,
cholesterol-enriched catabolic products of chylomicrons and
VLDL. Furthermore, a few HD patients also exhibit increased
levels of LDL cholesterol, among them very few patients with
a familiar history of hypercholesterolemia.
Beside the uncertainty of treatment, several clinical problems
emerge when trying to influence dyslipidemia with currently
available substances. Primarily, the drugs that have been tested
for lipid lowering in chronic renal failure are fibric acids.
Accumulation and severe side effects, such as muscle toxicity
and rhabdomyloysis [15, 16] have been reported. Although,
effective when used in adequate dosage [171 several authors do
not recommend fibric acid derivatives in patients with chronic
and end-stage renal failure [reviewed in 18]. Other substances
such as L-carnitine, low-molecular weight heparin and omega-
3-polyunsaturated fatty acids have been demonstrated to be
effective in lowering triglyceride and/or cholesterol in some
studies, but many results are contradictory [19—21].
To investigate the effects of HMG-CoA reductase inhibitors
in chronic renal failure we selected an unusual group of patients
with predominant elevations of cholesterol in VLDL and LDL.
We further studied the tolerance of lovastatin and simvastatin in




Forty patients with end-stage renal disease, who were en-
rolled in this study were on thrice weekly hemodialysis treat-
ment since 5,8 1.4 years (range 0.5 to 23 years); 36 patients
completed the study. About 700 patients were screened in order
to obtain the required number of patients who met the inclusion
criteria and volonteered to enter the trial. The inclusion criteria
were serum values for cholesterol > 260 mg/dl. Most of these
patients displayed moderate hypertriglyceridemia. Patients
with plasma triglyceride levels higher than 500 mg/dl were
excluded. Twenty-three out of 36 patients had LDL cholesterol
higher than 155 mg/dl. In the remaining 13 patients high levels of
cholesterol in VLDL were responsible for the elevation of total
cholesterol, required to fulfill the inclusion criteria. End-stage
renal failure was due to chronic glomerulonephritis (12), inter-
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stitial nephritis (9), small kidneys of unknown origin (7), poly-
cystic kidney degeneration (5), hypertension (4), rapid progres-
sive glomerulonephritis (I), Morbus Bourneville-Pringle (1) and
eclampsia (1). Excluded were patients with diabetes mellitus,
secondary hyperparathyroidism, unstable angina pectoris, re-
cent myocardial infarction, or congestive heart failure. None
had thyroid or hepatic disease except one patient of the
lovastatin group, who had a history of nonA-nonB hepatitis
with intermittent elevation of transaminases in the past. There-
fore, exclusion criteria did not allow to study old and multimor-
bid individuals with poor prognosis as well as diabetic patients
with triglycerides > 500 mg/dl and elevated VLDL cholesterol.
No patient was taking other specific hypolipidemic drugs.
Eighteen patients in the lovastatin group as well as eighteen
treated with simvastatin completed the trial and data could be
obtained for evaluation.
Study design
Patients were subdivided into two groups consisting of 20
patients each. Patients of group I were treated with lovastatin
and consisted of 11 females and 9 males (mean age 53.2 2.7,
range 34 to 70 years). After one month placebo baseline period,
therapy was started with 20 mg lovastatin day for one month,
followed by 40 mg day for another two months. Patients of
group II were treated with simvastatin and consisted of 11
females and 9 males (mean age 55.6 2.4, range 36 to 69 years).
Simvastatin was given in a dosage of 10 mg day1 during the
first month, followed by 20 mg for another month and 40 mg for
a third month. Tablets of lovastatin and simvastatin were
supplied by Merck Sharp & Dohme (Munich, Germany). Both
HMG-CoA reductase inhibitors were given as a single daily
dose in the evening. During the study the patients were advised
not to change their dietary habits. The current medication
consisting mainly of antihypertensive medication and phos-
phate binders was also not changed. The patients were inter-
viewed about any side effects of the medication, such as
anorexia, nausea, vomiting, abdominal pain, allergic reactions,
muscle cramps, myalgias. Special effort was undertaken to
ensure compliance in those patients. The study was carried out
according to the principles of the Declaration of Helsinki. All
patients gave their informed consent before entering the study
and the protocol for this study was approved by the appropriate
institutional review board.
Sampling procedure
Blood samples were collected in tubes without any anticoag-
ulant. All patients were studied after an overnight fast of at least
12-hours immediately before the start of hemodialysis at the
beginning of the study and in monthly intervals. The blood
samples were centrifuged within 30 minutes of collection. All
measurements for lipoprotein parameters were performed in
fresh serum. Routine hematologic and biochemical assessment
including a full and differential blood count, creatinine, urea,
sodium, potassium, phosphate, calcium, total bilirubin, blood
glucose, total bilirubin, alanine aminotransferase, aspartate
aminotransferase, alkaline phosphatase, creatine phosphoki-
nase (CK), gamma-glutamyltranspeptidase and lactate dehydro-
genase were carried out before the study, as well as in monthly
intervals and four weeks after completion of the study. EDTA-
plasma was obtained at the end of the third month in simvas-
tatin treated patients for determination of simvastatin (hydroxy-
acid-form) plasma levels [221.
Lipid determination
Cholesterol and triglycerides were determined enzymatically
using Boehringer Mannheim reagents (Cholesterol 704121, Tri-
glyceride 704113). Apolipoproteins A-i and B were determined
by kinetic nephelometry using comercial kits and the "Array"
nephelometer, both from Beckman (Palo Alto, California,
USA). As a reference material, lyophilized control serum, in
which the lipoproteins have been protected from denaturation
by addition of saccharose before lyophilization [23], was used.
Lipoprotein separation
An aliquot of serum was subjected to preparative ultracen-
trifugation as described in the Manual of Laboratory Opera-
tions of the Lipid Research Clinics Program [24]. Modifications
were performed as follows: very low density lipoproteins
(VLDL) were isolated in a Kontron ultracentrifuge (Rotor No.
TFT 45.6, in tubes of 1 cm diameter, volume 1.5 ml). Eight
tenths ml of serum was pipetted into the tube, the weight of the
tube was recorded and 0.2 ml of 0.9% NaCl solution was
layered above the serum. Centrifugation was performed for
exactly 18 hours at 30.000 rpm at 10°C. After centrifugation the
floated VLDL-fraction was aspirated by a 1 ml syringe until the
supernatant was completely clear. The volume was reconsti-
tuted to the original weight with 0.9% saline. The concentration
of VLDL lipids was calculated by the difference between the
concentrations of the different lipids in the serum and in the d =
1006 infranatant. The lipid composition of VLDL in the aspi-
rated specimen was determined directly. The concentration of
LDL-lipids was determined by the difference between VLDL-
free serum, obtained after ultracentrifugation, and the super-
natant of this fraction after precipitation of LDL by phospho-
tunctic acid/MgCl2. In addition to ultracentrifugation, HDL
cholesterol was determined by precipitation from whole serum
by the same procedure. All lipid determinations of the same
sample were performed sequentially on a Hitachi 704-analyzer.
The coefficient of variation for cholesterol and triglyceride as
well as the determination of LDL varied between 1 and 3%.
This low interassay coefficient of variation could not be ob-
tained by other technology used for lipoprotein quantation.
Therefore, the discribed technology was selected for the
present study.
Statistical analysis
The results are expressed as means SEM. Statistical anal-
ysis was performed by Student t-test for paired and unpaired
observations. P values less than 0.05 were considered to be
significant.
Results
The effects of sequentially increasing doses of lovastatin and
simvastatin on serum lipids and lipoproteins are shown in
Tables 1 and 2. Total serum cholesterol decreased by 21.3
2.6% (mean SEM) after one month on 20 mg of lovastatin
day and by 23.9 2.9% after another two months on 40 mg
day1 (P < 0.001). An even more pronounced effect could be
observed after treatment with 40 mg of simvastatin (Table 2).
Since the tubes have been layered with 0.9% sodium chloride (d
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Table 1. Effect of increasing doses of lovastatin on serum
cholesterol, triglycerides and their distribution in VLDL, LDL and
HDL in 18 HD patients
Placebo 20 mg 40 mg
Cholesterol 280.3 9.4 220.7 7,5b 213.0 67b
VLDL 72.4 8.9 55.6 74 47.3 6.8a
LDL 161.9 10,7 119.5 6.7" 112.1 7.9"
HDL 44.6 2.6 43.9 2.2 44.3 1.6
Triglyceride 329.6 35.6 305.1 37.0 311.5 49.9
VLDL 234.0 35,2 224.8 35.6 218.1 46.7
LDL 59.1 3.7 52,1 3.9 52.3 3.9
HDL 30.5 2.8 28.8 3.1 34.5 3.6
Placebo 10 mg 20 mg 40 mg
Cholesterol 295.0 12.2 225.3 10,lc 204.3 8.9c 202.3 8.9c
VLDL 78.3 11.1 59.9 95b 48.3 84b 50.7 8.8"
LDL 181.8 14.7 124.9 8.5' 115.7 8.3c 107.4 8.lc
HDL 34.9 2.7 40.6 2.9a 40.3 2.4a 44.2 35
Triglyceride 333.6 42.7 304.0 48.5a 258.5 41.8a 269.9 42.8a
VLDL 240.8 42.2 214.5 42.8 191.5 41.3 203.9 41.3
LDL 65.8 5.3 48.8 3,7C 44,3 3.2 43.1 4,3"
HDL 27.0 4.3 24.0 11.8 22.7 2.0 22.9 2.0
= 1.006g/ml) only lipoproteins exhibiting a hydrated density of
less than 1.006 were floating. Therefore the 1.006 infranate
contained IDL and LDL. Changes in total serum cholesterol
were paralleled by reductions in LDL cholesterol, total serum
apo B and apo B in LDL. LDL cholesterol fell by 24.1 3.1%
and 30.8 4.2% on doses of 20 and 40 mg of lovastatin and by
31.4 2.9%, 36.4 2.4% and 40.9 3.9% on doses of 10, 20
and 40 mg day' of simvastatin (P < 0.001 for both drugs).
Apo B levels are usually normal or subnormal in HD patients.
Normal values of our laboratory are in the range of 90 to 130
rng/di. Apo B was reduced significantly from 116.3 6.6 to 83.3
3.7 mg/dl (placebo vs. 40 mg day' lovastatin; P < 0.01) and
from 134.4 8.2 to 84.1 5.3 mg/dl (placebo vs. 40mg day
simvastatin; P < 0.01). Apo B in LDL fell by 26.0 3.8% and
40.3 4.1%, respectively (Fig. 1). Furthermore, a statistically
significant rise of the ratio of LDL apo B/LDL cholesterol from
0.63 0.02 to 0.71 0.05 was noted during lovastatin and from
0.63 0.02 to 0.66 0.02 during simvastatin treatment (Fig. 2).
Serum concentrations of HDL cholesterol were not altered in
lovastatin treated patients but increased significantly during the
third month of treatment with simvastatin (26.6 2.4%; P <
0.05). However, both groups of patients differed significantly by
their baseline (placebo) HDL cholesterol (P <0.05). Therefore,
the so-called atherogenic index, the ratio of LDL/HDL choles-
terol decreased from 3.6 0.3 to 2.5 0.2 during lovastatin and
Time, mont/IS
Fig. 1. The influence of increasing doses of lovastatin (open circles)
and simvastatin (solid circles) on apo B concentration in LDL in HD
patients. Data represent the mean SEM from 36 patients. c P <
0.00 1.
Placebo Drug
from 5.9 0.8 to 2.6 0.2 during simvastatin therapy (Fig. 3).
Consequently, serum values of apo A-i remained constant
during lovastatin 136.2 5.0 vs. 135.3 3.7 mg/dl) and







The last dose (40 mg) was given over a period of two months.
Data are given in mg/dl as mean SEM.
a P < 0.01
b P < 0.001
Table 2. Effect of increasing doses of simvastatin on serum
cholesterol, triglycerides and their distribution in VLDL, LDL and
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Each dose was given over a period of one month.
Data are given in mg/dl as mean SEM.
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Fig. 2. The influence of increasing doses of lovastatin (open circles)
and simvastatin (solid circles) on the ratio of apo B to cholesterol in
LDL in HD patients. Data represent the mean SEM from 36 patients.
a=P<0.05,b=P<0.01,c=P<0.00l.
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Fig. 3. The influence of increasing doses of lovastatin (open circles)
and simvastatin (solid circles) on the ratio of LDL cholesterol to HDL
cholesterol in HD patients. Data represent the mean SEM from 36
patients. b = P < 0.01.
increased after the third month of simvastatin therapy (121.4
6.1 vs. 145.9 9.1 mg/dl; P <0.01).
A pronounced lowering of cholesterol was observed in
VLDL during three months of treatment with the two HMG-
CoA reductase inhibitors (34.7 5.3% and 35.2 7.0%,
respectively). Therefore, the ratio of triglycerides/cholesterol in
VLDL increased significantly (3.25 0.15 vs. 3.84 0.18 and
3.18 0.18 vs. 4.05 0.18, respectively; Fig. 4).
Serum triglyceride metabolism is depicted in Tables 1 and 2.
The SEM values for total and VLDL triglycerides in the Tables
are higher compared to the other lipoprotein values. Six pa-
tients of group II (simvastatin) did not show any effect on total
and VLDL triglycerides. Nevertheless, an overall significant
reduction of total triglyceride was achieved by simvastatin
(—2 1.3%; P <0.05) and to a minor extent by lovastatin (—5.5%,
NS). The reduction of LDL triglycerides was most evident after
treatment with simvastatin (—34.5%; P < 0.01), whereas by-
astatin reduced triglycerides in LDL by 18.5% (NS). Therefore,
the ratio of triglycerides/cholesterol in LDL increased from 0.38
0.02 to 0.51 0.06 in the lovastatin group (P < 0.01), but
remained stable during treatment with simvastatin (0.41 0.03
vs. 0.42 0.03; Fig. 5).
Adverse effects
No major side effects in both study trials occurred. For
purpose of safety, all minor side effects are reported. Clinical
chemistry parameters were evaluated in monthly intervals.
There were no differences between placebo and lovastatin or
placebo and simvastatin treated patients with respect to alanine
aminotransferase, asparte aminotransferase, alkaline phos-
phatase, total bilirubin, creatine kinase, creatinine and urea.
Fig. 4. The influence of increasing doses of lovastatin (open circles)
and simvastatin (solid circles) on the ratio of triglyceride to cholesterol
in VLDL in HD patients. VLDL-triglyceride/cholesterol for this figure
was measured in VLDL isolated at d> 1.006 g/liter. Data represent the
mean SEM from 36 patients. a = P < 0.05, b = P < 0.01, c = P <
0.001.
There were four drop outs. One patient underwent kidney
transplantation during the third month of therapy. Another
patient was withdrawn from the study due to non-compliance to
medication. The third patient decided to leave the protocol due
to gastrointestinal disturbances and obstipation during the
placebo period. The fourth patient had to undergo aortic valve
replacement after completion of the first month of active
treatment. In all but one patient, liver enzymes remained
whithin normal limits. The patient with a history of nonA-nonB
hepatitis showed gradually increasing values of alanine ami-
notransferase and aspartate aminotransferase (third month: 190
and 53 U/liter, respectively). This elevation was completely
reversed two weeks after withdrawal of lovastatin. There was
no patient who experienced a continuous rise in creatine kinase
above normal. There were single peak values of creatine kinase
in four patients (73, 130, 134 and 138 U/liter, respectively;
normal values 0 to 70 U/liter) during the study. Enhanced
muscular activity in the dialysis interval or muscle cramps, as a
possible cause for CK-elevation, were not reported by the
patients before measurement. Two other patients had increased
CK-values before the study, which decreased (322 vs. 169
U/liter) or moderately increased (101 vs. 179 U/liter) during the
active treatment period. In all patients no muscular symptoms
were reported. One patient developed severe pruritus and
discontinued treatment one week before completing three
months of treatment. Blood was obtained for determination of
lipoproteins and serum chemistry and the values were taken as
a final sample. This patient experienced a slight but not sus-
tained release of the pruritus after discontinuation of therapy
Placebo Drug
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but symptoms did not disappear even two months after cessa-
tion of therapy making simvastatin-associated side effects un-
likely.
Accumulation
In 13 patients of group II plasma could be obtained after three
months of treatment with simvastatin (40 mg during the last
month) for determination of simvastatin plasma levels (hy-
droxy-acid form). Measurements were performed 13.4 1.5
hours after the administration of the drug. In five patients
values ranged from 4 to 15 ng!ml ten hours after the last dose.
One patient demonstrated a value of 45 ng/ml eleven hours after
the last dose in the absence of clinical and laboratory side
effects. In another six patients values ranged from 4 to 17 ng/ml
12 to 23 hours after the last simvastatin administration.
In a separate investigation, lovastatin and mevalonate deter-
minations were performed in ultrafiltrates of ten hemodialysis
patients after administration of a single dose of lovastatin (80
mg) three hours before hemodialysis. An ultrafiltrate sample
was obtained within 10 minutes after initiation of hemodialysis.
Mean inhibitory concentration in ultrafiltrates (using dialyzers
made of polysulfone, F60, Fresenius, Oberursel, Germany) was
significantly higher (14.7 2.9 nglml) after lovastatin as com-
pared to ultrafiltrates from the same patients taking no lovasta-
tin (3.6 0.5 ng/ml; P < 0.05). Mevalonate concentration in
ultrafiltrates were also higher after lovastatin (16.6 4.0 ng/ml)
as compared to ultrafiltrates from controls (11.8 4.5 ng/ml).
Discussion
The effect of HMG-CoA reductase inhibitors on plasma
lipoproteins, lipids and apolipoproteins in hypercholesterolemic
HD patients is described. It should be emphasized that screen-
ing of 700 HD patients was necessary to select 40 patients
displaying hypercholesterolemia associated with mild hyper-
triglyceridemia. Lovastatin and simvastatin effectively reduced
total and LDL cholesterol and increased HDL cholesterol in
patients on hemodialysis, so the overall effect of HMG-CoA
reductase inhibition on the LDL/HDL ratio appeared favorable.
Therefore, the effects of the two HMG-CoA reductase inhibi-
tors on these lipoproteins are in general agreement with those
from investigation in nonuremic individuals, where lovastatin
and simvastatin have been shown to consistantly lower total
and LDL cholesterol [25]. Another remarkable effect of choles-
terol synthesis inhibition was the reduction of cholesterol in
VLDL. Consequently, the ratio of triglycerides/cholesterol in
VLDL increased.
The major dyslipidemia of patients with chronic renal failure
is an increase in plasma triglycerides [26, 27]. Generally,
triglyceride levels are between 200 and 600 mg/dl, and eleva-
tions occur mainly in VLDL, although intermediate density
lipoproteins (IDL) may be increased and, also LDL are en-
riched in triglycerides [reviewed 281. In this group of HD
patients the weight of published evidence also suggests that
remnants of triglyceride rich lipoproteins and not LDL are the
atherogenic particles [13, 14, 29]. It has been shown that
HMG-CoA reductase inhibitors are effective in Type III hyper-
lipoproteinemia. However, Type III hyperlipoproteinemia and
the hyperlipoproteinemia in renal disease are comparable only
in that IDL may accumulate. Such IDL in these two patient
groups are entirely different in structure with the presence of
receptor-defective E2 in type III IDL. Furthermore, in uremic
patients apo-C-III is elevated and apo-C-II and E are decreased.
Windler, Chao and Havel [30] recently demonstrated that the
relative concentrations of the C and E apolipoproteins carried
by triglyceride-rich lipoproteins affect remnant removal from
plasma. HMG-CoA reductase inhibitors induce the expression
of the LDL receptor on liver cells. Therefore, apo B/E rich
lipoproteins could effectively be metabolized upon HMG-CoA
reductase inhibition. It should be noted that the patients Se-
lected in this study were not typical hemodialysis patients in
regard to their lipoprotein pattern, They also exhibited elevated
levels of LDL and VLDL cholesterol. The underlying method-
ology did not permit discriminate between IDL and LDL.
Lipoproteins exhibiting a hydrated density of less than 1.006
g/ml were floating and the 1.006 infranate contained IDL and
LDL. In addition to the marked reduction of LDL cholesterol,
also cholesterol content in VLDL was profoundly reduced by
lovastatin and simvastatin (Tables 1 and 2). Consequently, the
ratio of triglycerides to cholesterol in VLDL normalized, indi-
cating VLDL formation rich in triglycerides and poor in cho-
lesterol. However, it remaines to be proven that HMG-CoA
reductase inhibitors influence IDL in this patient type.
The effects of lovastatin and simvastatin on HDL cholesterol
were variable. The results are in general agreement with studies
in nephrotic syndrome. Two trials with low baseline HDL
levels reported increases in HDL cholesterol after HMG-CoA









Fig. 5. The influence of increasing doses qf lovastatin (open circles)
and simvastatin (solid circles) on the ratio of triglyceride to cholesterol
in LDL in HD patients. Data represent the mean SEM from 36
patients. a = P <0.05, b = P < 0.01.
—1 0 1 2 3
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baseline HDL levels found little changes after treatment with
HMG-CoA reductase inhibitors [33, 34]. The same effect was
observed in the present study.
Few adverse effects were seen in the present study. No
patient developed a complication necessitating cessation of
therapy. It has been demonstrated that the elimination of
lovastatin and simvastatin occurs primarily by the liver and
dose reduction has not been recommended in renal insuffi-
ciency. However, interference with their transport into bile, by
either concomitant drug therapy, could raise blood levels and
predispose to accumulation and myopathy [18]. Therefore, this
group of patients, who were especially prone to muscular
damage and side effects, were monitored closely in the present
study to detect complications early. On the other hand, it is not
known to what extent excess myoglobin released into the
circulation does any harm to an individual whithout excretory
renal function. Extensive hemodialysis using membrane mate-
rial with high cut-off rates should overcome excess myoglobin
levels sufficiently. Hagemenas, Papu and Illingworth [35]
showed that 100 mg of C'4 simvastatin given in a single dose to
healthy subjects was completely cleared from the circulation
after 12 hours. In several of our patients inhibitory activity of
simvastatin could be detected in plasma even 15 hours after
simvastatin administration, and in one patient a marked in-
creased value was observed at 11 hours after simvastatin
administration. None of the patients with detectable levels of
simvastatin in plasma had evidence for clinical side effects or
laboratory abnormalities. Since lovastatin is removed in small
quantities in the dialysis fluid, it might help to reduce toxicity.
Nevertheless, these data suggest that dose reduction should be
recommended for HD patients treated with HMG-CoA reduc-
tase inhibitors.
In summary, lovastatin and simvastatin profoundly affect the
composition of lipoprotein particles in selected HD patients
with hypercholesterolemia and mild hypertriglyceridemia.
There is a reduction of the total cholesterol and cholesterol
content in VLDL as well as a normalization of the ratio of
triglycerides to cholesterol in VLDL. Triglyceride content of
the various particles was only affected in some patients treated
with simvastatin. In this short term study the two cholesterol
synthesis inhibitors had only few side effects and no clinical
signs of drug accumulation were observed. It appears that there
are only a few selected patients with high serum cholesterol
level among all RD patients who could be candidates for this
kind of treatment. However, more research is needed to define
safe drug dosages for treatment of patients on dialysis.
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